CoChat

The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma

Open access
Coulson, Rhiannon, Liew, Seng H., Connelly, Angela A., Yee, Nicholas S., Deb, Siddhartha, Kumar, Beena, Vargas, Ana C., O’Toole, Sandra A., Parslow, Adam C., Poh, Ashleigh, Putoczki, Tracy, Morrow, Riley J., Alorro, Mariah, Lazarus, Kyren A., Yeap, Evie F.W., Walton, Kelly L., Harrison, Craig A., Hannan, Natalie J., George, Amee J., Clyne, Colin D., Ernst, Matthias, Allen, Andrew M., Chand, Ashwini L. · 2017 · Oncotarget
Cited by 96

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

// Rhiannon Coulson 1,8 , Seng H. Liew 2 , Angela A. Connelly 3 , Nicholas S. Yee 4 , Siddhartha Deb 5 , Beena Kumar 6 , Ana C. Vargas 7 , Sandra A. O’Toole 7,8,9 , Adam C. Parslow 10,16 , Ashleigh Poh 11 , Tracy Putoczki 11 , Riley J. Morrow 4 , Mariah Alorro 4 , Kyren A. Lazarus 1,12 , Evie F.W. Yeap 1 , Kelly L. Walton 13 , Craig A. Harrison 13 , Natalie J. Hannan 14 , Amee J. George 15 , Colin D. Clyne 1 , Matthias Ernst 4,16 , Andrew M. Allen 3 and Ashwini L. Chand 1,4,16 1 Cancer Drug Discovery, Hudson’s Institute of Medical Research, Clayton, VIC, Australia 2 Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia 3 Department of Physiology, University of Melbourne, VIC, Australia 4 Cancer and Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia 5 Anatomical Pathology, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia 6 Anatomical Pathology, Monash Health, Clayton, VIC, Australia 7 Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, NSW, Australia 8 Translational Breast Cancer Research, Garvan Institute, Darlinghurst, Sydney, NSW, Australia 9 Sydney Medical School, Sydney University, NSW, Australia 10 Tumor Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia 11 Inflammation Division, WEHI, VIC, Australia 12 Department of Pharmacology, University of Cambridge, Cambridge, UK 13 Department of Physiology, Monash University, Clayton, VIC, Australia 14 Translational Obstetrics Group, Department of Obstetrics and Gynaecology, University of Melbourne, Mercy Hospital, Heidelberg, VIC, Australia 15 The ACRF Department of Cancer Biology and Therapeutics, John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia 16 School of Cancer Medicine, La Trobe University, Heidelberg, VIC, Australia Correspondence to: Ashwini L. Chand, email: // Keywords : invasive ductal carcinoma, luminal breast cancer, angiotensin receptor, interleukin 6, tumor necrosis factor Received : November 21, 2016 Accepted : February 07, 2017 Published : February 20, 2017 Abstract Drugs that target the Renin-Angiotensin System (RAS) have recently come into focus for their potential utility as cancer treatments. The use of Angiotensin Receptor Blockers (ARBs) and Angiotensin-Converting Enzyme (ACE) Inhibitors (ACEIs) to manage hypertension in cancer patients is correlated with improved survival outcomes for renal, prostate, breast and small cell lung cancer. Previous studies demonstrate that the Angiotensin Receptor Type I (AT 1 R) is linked to breast cancer pathogenesis, with unbiased analysis of gene-expression studies identifying significant up-regulation of AGTR1, the gene encoding AT 1 R in ER +ve /HER2 -ve tumors correlating with poor prognosis. However, there is no evidence, so far, of the functional contribution of AT 1 R to breast tumorigenesis. We explored the potential therapeutic benefit of ARB in a carcinogen-induced mouse model of breast cancer and clarified the mechanisms associated with its success. Mammary tumors were induced with 7,12-dimethylbenz[α]antracene (DMBA) and medroxyprogesterone acetate (MPA) in female wild type mice and the effects of the ARB, Losartan treatment assessed in a preventative setting ( n = 15 per group). Tumor histopathology was characterised by immunohistochemistry, real-time qPCR to detect gene expression signatures, and tumor cytokine levels measured with quantitative bioplex assays. AT 1 R was detected with radiolabelled ligand binding assays in fresh frozen tumor samples. We showed that therapeutic inhibition of AT 1 R, with Losartan, resulted in a significant reduction in tumor burden; and no mammary tumor incidence in 20% of animals. We observed a significant reduction in tumor progression from DCIS to invasive cancer with Losartan treatment. This was associated with reduced tumor cell proliferation and a significant reduction in IL-6, pSTAT3 and TNFα levels. Analysis of tumor immune cell infiltrates, however, demonstrated no significant differences in the recruitment of lymphocytes or tumour-associated macrophages in Losartan or vehicle-treated mammary tumors. Analysis of AT 1 R expression with radiolabelled ligand binding assays in human breast cancer biopsies showed high AT 1 R levels in 30% of invasive ductal carcinomas analysed. Furthermore, analysis of the TCGA database identified that high AT 1 R expression to be associated with luminal breast cancer subtype. Our in vivo data and analysis of human invasive ductal carcinoma samples identify the AT 1 R is a potential therapeutic target in breast cancer, with the availability of a range of well-tolerated inhibitors currently used in clinics. We describe a novel signalling pathway critical in breast tumorigenesis, that may provide new therapeutic avenues to complement current treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.15553

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 96

Metadata

Authors
Coulson, R., Liew, S. H., Connelly, A. A., Yee, N. S., Deb, S., Kumar, B., Vargas, A. C., O’Toole, S. A., Parslow, A. C., Poh, A., Putoczki, T., Morrow, R. J., Alorro, M., Lazarus, K. A., Yeap, E. F. W., Walton, K. L., Harrison, C. A., Hannan, N. J., George, A. J., Clyne, C. D., Ernst, M., Allen, A. M., & Chand, A. L.
Venue
Oncotarget
Published
2017-02-20
Volume
8
Issue
12
Pages
18640-18656
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2589308094
Cited by
96
References
8
FWCI
6.34
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. https://app.cochat.ai/papers/10.18632/oncotarget.15553
The paper
Coulson, R., Liew, S. H., Connelly, A. A., Yee, N. S., Deb, S., Kumar, B., Vargas, A. C., O’Toole, S. A., Parslow, A. C., Poh, A., Putoczki, T., Morrow, R. J., Alorro, M., Lazarus, K. A., Yeap, E. F. W., Walton, K. L., Harrison, C. A., Hannan, N. J., George, A. J., . . . Chand, A. L. (2017). The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget. https://doi.org/10.18632/oncotarget.15553

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.